Faculty profile

Susan Fox

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Susan Fox

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
18 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.
Supervised 1 trainee who won CIHR awards, most recently in 2010.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Adaptive Trials Biostatistics Clinical Trials Hqp Development Job Shadowing Mentorship Pedogagy Training

Latest papers

Gender Disparity in Movement Disorders Research Authorship: Progress and Persistent Gaps Across a Decade.
Movement disorders : official journal of the Movement Disorder Society · 2026
Cognitive, Motor and Oculomotor Contributions to the Trail Making Test in Progressive Supranuclear Palsy.
Movement disorders clinical practice · 2026
Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

All 46 publications

Latest funding

Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)
CIHR · 2022 · Principal investigator
$4,314,242
Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)
CIHR · 2022 · Principal investigator
$1,078,562
Preclinical efficacy of drugs predicted by IBM-Watson artificial intelligence for repurposing to treat L-DOPA-induced dyskinesia
CIHR · 2017 · Co-investigator
$160,650

All 6 grants and awards

46 publications.

Gender Disparity in Movement Disorders Research Authorship: Progress and Persistent Gaps Across a Decade.

Garg D, Aldaajani Z, Auffret M, Capato T, Picillo M, Trenkwalder C, Ali L, Armstrong MJ, Bruno M, Bruno V, Minakawa EN, Kamel WA, Fox S, Olszewska DA, Steering Committee of the MDS Women in Movement Disorders Special Interest Group

Movement disorders : official journal of the Movement Disorder Society2026

DOI: 10.1002/mds.70507 PMID: 42680703

Cognitive, Motor and Oculomotor Contributions to the Trail Making Test in Progressive Supranuclear Palsy.

Garcia-Cordero I, Hadian M, Vargas-Gonzalez JC, Monteiro M, Gold D, Khoja A, Morales-Rivero A, Couto B, Tang-Wai D, Fox S, Kovacs GG, Lang AE, Tartaglia MC

Movement disorders clinical practice2026

DOI: 10.1002/mdc3.70696 PMID: 42223071

Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease.

Mirza SS, Duff-Canning S, Mapstone M, Fox S, Black SE, Binns MA, Breen DP, Fishman KN, Grimes DA, Lang AE, Levine B, McLaughlin PM, Troyer AK, Masellis M, Marras C

Alzheimer's & dementia : the journal of the Alzheimer's Association2025

DOI: 10.1002/alz.70912 PMID: 41388800

Gender disparity in Canadian Institutes of Health Research funding within neurology.

Tao B, Tsai CC, Wang C, Vosoughi AR, Bui E, Chapman KM, Fox S, Khosa F

BMJ leader2025

DOI: 10.1136/leader-2023-000893 PMID: 39532389

Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.

Silveira CRA, Coleman KKL, Borron K, Tirona RG, Rupar CA, Zou G, Hegele RA, Wellington C, Stukas S, Finger EC, Bartha R, Morrow SA, Wells JL, Borrie MJ, Mahuran D, MacDonald PA, Jenkins ME, Jog MS, Dresser G, Fox S, Camicioli R, Feagan B, Mendonça DA, Mayich M, Sharma MD, Pandey SK, Pasternak SH

JAMA neurology2025

DOI: 10.1001/jamaneurol.2025.1687 PMID: 40587145

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.

Lee S, Yin L, Xiao N, Rhee TG, Lo HKY, Wong S, Fox S, Teopiz K, Lam BY, Zheng YJ, Le GH, Mansur RB, Rosenblat JD, McIntyre RS

CNS spectrums2025

DOI: 10.1017/s109285292510031x PMID: 40485141

The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.

Morales-Rivero A, Garcia-Cordero I, Khoja A, Vargas-Gonzalez JC, Couto B, Antwi J, Sasitharan J, Bhakta P, Kovacs GG, Fox S, Tang-Wai DF, Lang AE, Tartaglia MC

European journal of neurology2025

DOI: 10.1111/ene.70248 PMID: 40525323

Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy.

Wang J, Forrest SL, Dasari S, Tanaka H, Rogaeva E, Tartaglia MC, Fox S, Lang AE, Kalyaanamoorthy S, Kovacs GG

Immunobiology2025

DOI: 10.1016/j.imbio.2025.152892 PMID: 40132252

Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.

Kalia LV, Asis A, Arbour N, Bar-Or A, Bove R, Di Luca DG, Fon EA, Fox S, Gan-Or Z, Gommerman JL, Kang UJ, Klawiter EC, Koch M, Kolind S, Lang AE, Lee KK, Lincoln MR, MacDonald PA, McKeown MJ, Mestre TA, Miron VE, Ontaneda D, Rousseaux MWC, Schlossmacher MG, Schneider R, Stoessl AJ, Oh J

Nature reviews. Neurology2024

DOI: 10.1038/s41582-024-01023-0 PMID: 39375563

Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.

Garcia-Cordero I, Anastassiadis C, Khoja A, Morales-Rivero A, Thapa S, Vasilevskaya A, Davenport C, Sumra V, Couto B, Multani N, Taghdiri F, Anor C, Misquitta K, Vandevrede L, Heuer H, Tang-Wai D, Dickerson B, Pantelyat A, Litvan I, Boeve B, Rojas JC, Ljubenkov P, Huey E, Fox S, Kovacs GG, Boxer A, Lang A, Tartaglia MC, 4‐R‐Tauopathy Neuroimaging Initiative Consortium, and the Alzheimer's Disease Neuroimaging Initiative

Annals of neurology2024

DOI: 10.1002/ana.26930 PMID: 38578117

Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)

Principal investigatorCIHR2022Training Grant: Clinical Trials Training Platforms

Principal investigators: Cheung, Angela M; Ahmed, Sofia B; Allen, Upton D; Bhat, Mamatha; Boyd, Steven K; Crawley, Angela M; Dolatabadi, Elham; Fahim, Christine; Farkouh, Michael E; Feld, Jordan J; Fox, Susan; Furlan, Andrea D; Goligher, Ewan C; Hodgson, David C; Inman, Robert D; Juando Prats, Clara; Lamontagne, Francois; Langlois, Marc-Andre; Levin, Adeera; Mansfield, Avril; Manske, Sarah L; McMaster, W. Robert; Mylopoulos, Maria; Oza, Amit M; Papaioannou, Alexandra; Pinto, Andrew D; Quinn, Kieran L; Rahman, Proton; Razak, Fahad; Richard, Nicolas; Richardson, Harriet; Sander, Beate H; Sellmann, Susanna; Stelfox, Henry T; Straus, Sharon E; Tartaglia, Maria Carmela; Tobe, Sheldon W; Tomlinson, George A; Verma, Amol; Walmsley, Sharon L; Wu, Robert; Xu, Wei

Keywords: Adaptive Trials; Biostatistics; Clinical Trials; Hqp Development; Job Shadowing; Mentorship; Pedogagy; Training

$4,314,242

Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)

Principal investigatorCIHR2022Training Grant: Clinical Trials Training Platforms - Indirect Costs

Keywords: Adaptive Trials; Biostatistics; Clinical Trials; Hqp Development; Job Shadowing; Mentorship; Pedogagy; Training

$1,078,562

Preclinical efficacy of drugs predicted by IBM-Watson artificial intelligence for repurposing to treat L-DOPA-induced dyskinesia

Co-investigatorCIHR2017Project Grant

Principal investigators: Lang, Anthony E

Keywords: Animal Model; Artificial Intelligence; Drug Repurposing; L-Dopa-Induced Dyskinesia; Machine Learning; Parkinson'S Disease

$160,650

Predicting outcome in Parkinson's disease cognitive impairment

Co-investigatorCIHR2012Operating Grant

Principal investigators: Marras, Connie; Duff Canning, Sarah J

Keywords: Cognition; Parkinson'S Disease

$584,214

Mechanistic study of the anti-dyskinetic action of the dopaminergic D4 receptor antagonist L-745,870 in the 6-OHDA-lesioned rat model of Parkinson's disease

SupervisorCIHR2010CIHR Fellowship

Principal investigators: Huot, Philippe

Keywords: 6-Ohda; 870; D4 Receptor; Dopamine; Dyskinesia; Glutamate; In Vivo Microdialysis; L-745; L-Dopa; Parkinson'S Disease; Rat

$110,000

Exploring the disease-modifying potential of calcium channel blockers in Parkinson's disease: Using population-based administrative data to inform clinical trials.

Co-investigatorCIHR2008Operating Grant

Principal investigators: Marras, Connie

Keywords: Health Services Research; Parkinson'S Disease; Prognosis; Treatment

$65,453

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Susan Fox

Research

Latest papers

Latest funding

Gender Disparity in Movement Disorders Research Authorship: Progress and Persistent Gaps Across a Decade.

Cognitive, Motor and Oculomotor Contributions to the Trail Making Test in Progressive Supranuclear Palsy.

Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease.

Gender disparity in Canadian Institutes of Health Research funding within neurology.

Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.

The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.

Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy.

Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.

Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.

Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)

Canadian Training Platform for Trials Leveraging Existing Networks (CAN-TAP-TALENT)

Preclinical efficacy of drugs predicted by IBM-Watson artificial intelligence for repurposing to treat L-DOPA-induced dyskinesia

Predicting outcome in Parkinson's disease cognitive impairment

Mechanistic study of the anti-dyskinetic action of the dopaminergic D4 receptor antagonist L-745,870 in the 6-OHDA-lesioned rat model of Parkinson's disease

Exploring the disease-modifying potential of calcium channel blockers in Parkinson's disease: Using population-based administrative data to inform clinical trials.

Frequent collaborators

Connie Marras

Sarah Duff Canning

Nancy Kennedy

Ekaterina Rogaeva

Robert Chen

Anthony Lang

Davide Martino

Christopher Meaney

Guangyong Zou

Raphael Schneider

David Grimes

Geoff Anderson

Brian Feagan

Robert Bartha

Mario Masellis

Antonio Strafella

Nathalie Arbour

Brian Hutton

Pablo Rusjan

Andres Lozano

Sabrina Wong

Tolulope Sajobi

Tiago Mestre

Silke Appel-Cresswell

Michael Schlossmacher

Jiwon Oh

Alfonso Fasano